证券日报网讯 1月28日，金域医学发布公告称，金域医学2025年前三季度利润分配方案：A股每股派发 现金红利0.88元（含税），股权登记日2026年2月4日，除权除息日及红利发放日均为2026年2月5日，总 计派息约4.08亿元。 （编辑 丛可心） ...

证券之星消息，截至2026年1月28日收盘，国际医学(000516)报收于4.99元，下跌1.58%，换手率 2.17%，成交量47.81万手，成交额2.39亿元。 国际医学2025年三季报显示，前三季度公司主营收入29.95亿元，同比下降16.94%；归母净利润-2.94亿 元，同比下降38.45%；扣非净利润-3.12亿元，同比下降41.94%；其中2025年第三季度，公司单季度主 营收入9.61亿元，同比下降18.95%；单季度归母净利润-1.29亿元，同比下降234.24%；单季度扣非净利 润-1.23亿元，同比下降52.03%；负债率68.8%，投资收益2075.86万元，财务费用1.11亿元，毛利率 6.59%。国际医学（000516）主营业务：大健康医疗服务和现代医学技术转化应用。 1月28日的资金流向数据方面，主力资金净流出3864.74万元，占总成交额16.15%，游资资金净流出 149.37万元，占总成交额0.62%，散户资金净流入4014.11万元，占总成交额16.78%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 该股最近90天内共有2家机构给出评级，增持评级2家；过 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 调研基本情况 2026年1月28日15:00-16:00，天津九安医疗电子股份有限公司（以下简称"九安医疗"）通过电话会议方 式举办投资者线上交流会，接待了农银汇理、南方基金、大成基金、博时基金、前海开源、新华基金、 招商基金、光大保德信等8家机构。公司董事会秘书邬彤出席会议，就产品研发、糖尿病诊疗照 护"O+O"新模式、AIoT糖尿病家庭医助项目、科创投资及股东回报规划等事项与机构投资者进行沟 通。 核心议题解读 IVD产品进展：四联检试剂盒美国上市，智能助听器研发中 在产品研发方面，九安医疗介绍，IVD产品领域的iHealth四联检试剂盒已于2025年12月获得美国FDA 510(k)上市前通知，目前已在CVS开始销售，同时可通过亚马逊线上渠道订购。亚马逊平台显示，该产 品两人份售价29.99美元，四人份售价49.99美元（预售结束后定价54.99美元）。公司表示，该产品拓展 了试剂盒类产品的可检测病毒类别，有助于满足美国市场呼吸道病毒筛查多元化需求，提升核心竞争 力。值得注意的是，510(k)属于常规上市许可，不受EUA终止影响，可在美持续销售。 此外， ...

Core Viewpoint - The establishment of Shenzhen Skin Disease Hospital fills a gap in specialized skin disease treatment in Shenzhen, addressing the growing demand for skin health services in the region [1][2]. Group 1: Hospital Overview - Shenzhen Skin Disease Hospital is a tertiary specialized hospital with a construction area of nearly 34,000 square meters and plans for 100 beds, focusing on various skin conditions [1]. - The hospital will offer 13 specialized outpatient services, including acne, hair loss, allergic skin diseases, and psoriasis, to meet diverse patient needs [1]. Group 2: Demand for Skin Health Services - The demand for skin disease treatment in Shenzhen is estimated at 3 million visits annually, highlighting a significant service gap due to insufficient existing medical resources [2]. - A recent epidemiological survey identified the top six skin concerns among Shenzhen residents, including acne and androgenetic alopecia, with nearly 25% of the population suffering from acne [2]. Group 3: Research and Development - The Shenzhen Chronic Disease Prevention Center, with over 50 years of experience, supports the hospital's development and has established a skin disease research institute that leads in outpatient volume [3]. - The research institute focuses on three key disciplines: dermatological pharmacology, dermatopathology and imaging, and dermatological epidemiology, utilizing advanced technologies for early diagnosis and intervention [3]. Group 4: Technological Advancements - The hospital employs non-invasive diagnostic methods such as skin ultrasound and CT, enhancing patient comfort while ensuring accurate diagnoses [4]. - It has developed over 30 proprietary traditional Chinese medicine formulations for various skin conditions, emphasizing specialized treatment [3]. Group 5: Future Plans and Growth - The hospital aims to double its outpatient visits to 600,000 by 2030 and plans to establish a high-level research-oriented dermatology center with multiple specialized centers [8]. - The introduction of "star formulations" and a focus on integrating traditional Chinese medicine with Western practices are key strategies for enhancing treatment options [8]. Group 6: Role in Medical Aesthetics - Shenzhen Skin Disease Hospital plays a crucial role in supporting the city's ambition to become a "medical beauty capital," with a significant market presence in the medical aesthetics industry [7]. - The hospital is involved in setting industry standards and providing training to ensure safety and professionalism in the medical aesthetics sector [7].

Group 1 - The core point of the article is that Shanghai Anze has completed a share reduction plan, decreasing its holdings in the company by approximately 3.09 million shares, which represents about 0.99% of the total share capital as of December 10, 2025 [1] - From December 4 to December 17, 2025, Shanghai Anze reduced its shares by approximately 2.09 million shares through centralized bidding, which is 0.99% of the total share capital [1] - On January 28, 2026, Shanghai Anze further reduced its holdings by 1 million shares through block trading, accounting for 0.48% of the total share capital as of January 20, 2026 [1] Group 2 - After the completion of the share reduction, Shanghai Anze holds approximately 9.01 million shares, which is 4.29% of the total share capital as of January 20, 2026 [1] - The share reduction plan has been fully implemented, indicating a strategic decision by Shanghai Anze regarding its investment in the company [1]

Core Viewpoint - The A-share market is experiencing fluctuations, with the Shanghai Composite Index showing resistance at the 4160-4170 point range, indicating a mixed sentiment among investors [6][8]. Market Performance - The A-share market saw 1,736 stocks rise while 3,637 stocks fell, reflecting a continued low profitability environment for investors [7]. - The trading volume in both markets decreased slightly, with a focus on resource and technology sectors, particularly in gold, non-ferrous metals, and oil [9]. Sector Analysis - The gold and non-ferrous metal sectors experienced a surge, while sectors like photovoltaic equipment, medical services, and commercial aerospace faced declines [8]. - Defensive positioning is becoming a consensus among institutions, with a shift from sectors like photovoltaics and pharmaceuticals to safer assets such as gold and oil [11]. Investor Sentiment - Mainstream funds saw a net inflow of 15.9%, while retail investors had a net inflow of 396.2 million [10]. - Retail investors are exhibiting a cautious stance, with 49.5% choosing to hold their positions and a significant portion avoiding small-cap stocks [12][13]. Trading Behavior - The market is characterized by a lack of strong buying momentum, with a notable decrease in short-term speculative trading activities [11].

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Tongce Medical (600763), indicating a decline in stock price and mixed capital flow trends [1][2] - As of January 28, 2026, Tongce Medical's stock closed at 45.17 yuan, down 2.08%, with a turnover rate of 1.96% and a trading volume of 87,700 hands, resulting in a transaction amount of 398 million yuan [1] - In terms of capital flow on January 28, 2026, the net outflow of main funds was 41.39 million yuan, accounting for 10.39% of the total transaction amount, while retail investors saw a net inflow of 69.01 million yuan, representing 17.33% of the total transaction amount [1] Group 2 - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [2] - The third quarter of 2025 showed a single-quarter main revenue of 842 million yuan, reflecting a year-on-year increase of 2.34%, with a net profit of 192 million yuan, also up 2.31% year-on-year [2] - The company has a debt ratio of 25.1%, investment income of 41.22 million yuan, financial expenses of 31.93 million yuan, and a gross profit margin of 41.69% [2] Group 3 - Over the past 90 days, five institutions have provided ratings for Tongce Medical, with three buy ratings and two hold ratings, and the average target price set by institutions is 52.15 yuan [2]

Group 1 - The core idea of the news is the launch of the "Luyun Emergency Rescue" project by Shandong Mobile Liaocheng Development Zone Branch in collaboration with Liaocheng Maternal and Child Health Hospital, utilizing 5G technology to enhance emergency medical services and create a digital and intelligent upgrade for life health [1][2] - The project addresses the efficiency bottlenecks of traditional emergency response by enabling residents to use a "one-click emergency call" for quick and accurate location identification, significantly reducing inquiry and dispatch time [1] - The initiative includes the development of a "mobile rescue room" that leverages 5G technology for real-time monitoring and remote video consultation, allowing medical data to be transmitted to hospitals before the patient arrives, thus facilitating immediate treatment upon arrival [1] Group 2 - This collaboration exemplifies the "Internet + Emergency Rescue" service model and reflects the commitment to a people-centered development approach [2] - Shandong Mobile Liaocheng Development Zone Branch plans to continue leveraging 5G technology to enhance cooperation with hospitals, improve the smart emergency network, and expand functionalities such as AED location dispatch and volunteer coordination [2] - The goal is to promote comprehensive coverage and efficient upgrades of emergency services, ensuring the protection of residents' health through intelligent solutions [2]

近年来,聊城市立足卫生健康事业高质量发展需求,聚焦人才队伍建设关键环节,系统构建思想铸魂、能力 赋能、协同聚力"三位一体"培训体系,通过分层分类施训、资源上下贯通、公私有机关联等创新举措,逐 步形成目标清晰、路径明确、运行高效、整体协同的培训工作新格局,着力锻造一支人民群众信赖满意 的医疗卫生主力军。 聊城市坚持将提升政治素养与专业能力作为人才培养的双重支撑,建立"常态化思政教育+精准化业务培 训"协同机制。 在思想引领上持续发力。通过举办专题读书班、高层次思政培训班、主题研讨交流等活动,持续强化理 论武装、淬炼党员初心,引导医疗卫生工作者牢固树立以人民健康为中心的服务理念。 在专业提升上精准施策。打造"卫健大讲堂""院长管理在线"等学习平台,累计邀请国家级、省级专家30 余人次授课,围绕公立医院改革、现代医院管理、医疗质量安全等实践课题,促进政策理论与一线实务深 度融合。 □ 金增秀 思想能力双轮驱动 筑牢人才"立身之本" 在实践转化上创新模式。实施青苗锻造、链上提能、智库联动等培养模式,选派骨干到关键岗位锻炼,组 织人员赴先进地区观摩学习,依托卫生健康智库开展"院士专家聊城行"等活动,推动学习成果转化为解 ...

中国"1+8+N"战略推进以及海外业务持续双位数增长，共同驱动公司整体收入持续提升。国内业务方 面，公司于2022 年提出新十年"1+8+N"战略，即着力打造1 家世界级眼科医学中心（长沙爱尔）、8 家 国家及区域眼科医学中心（北京、上海、广州、深圳、成都、重庆、武汉、沈阳）、N 家省域一流和地 区领先的眼科医院。截至1H25末，公司境内医院355 家，门诊部240 家。展望未来，随着"1+8+N"战略 的推进和落地，我们相信重点医院辐射作用有望持续加强，门店布局有望完善丰富，带动集团中国收入 持续增长。海外业务方面，公司海外收入于2020-2024 年间实现17.6% CAGR，1H25 实现16.5%YoY 增 速，主要受欧洲子公司Clínica Baviera 和东南亚子公司ISEC 收入增长驱动。展望未来，国际市场空间潜 力巨大，随着公司现有海外业务收入的进一步提升以及未来潜在的海外并购落地，我们认为国际化收入 可在中长期助推公司收入增长。 首次覆盖给予"买入"评级及医疗服务行业首选推荐，目标价人民币14.0 元。我们预计公司于 2025E/2026E/2027E 实现228/250/273亿元收入， ...